The Lancet Commission “Dementia Prevention, Intervention and Care” published its report on 20 July 2017 in the prestigious journal Lancet (Livingston et al., Lancet, published online July 20, 2017). The authors describe dementia as the “greatest global challenge to health and social systems in the 21st century”.
Bild: Dirk Maus / pixelio.de
Restlessness and aggression are a particular burden not only for those affected, but especially for the caregivers of people who are suffering from Alzheimer’s disease. These symptoms, which include anxiety, irritability, depression, apathy, disinhibition, delusions and hallucinations, and disturbances of sleep and appetite, are summarized as Behavioral and Psychological Symptoms of Dementia (BPSD).
In the current issue of the prestigious British medical journal Lancet (published September 19, 2015) a remarkable editorial entitled „Alzheimergate? When miscommunication met sensationalism“ was published. In this editorial reference is made to an article that was published on September 10, 2015, in the no less prestigious science journal Nature, which apparently for many journalists suggested that Alzheimer’s disease is contagious in humans. What had happened? Continue reading
In the current issue of the New England Journal of Medicine, a consortium of scientists from Seattle and Boston reports on their large longitudinal study on the relationship between blood glucose and dementia risk (Crane et al., N Engl J Med 2013; 369: 540-548). Continue reading
The “Antidementia Drugs” are not discussed in the chapter “Psychotropic Drugs” of the Drug Prescription Report 2012 (see my posts from November 9th, 2012, from December 16th, 2012 and from January 19th, 2013), but in a separate chapter. This chapter was not written by Martin Lohse and Bruno Müller-Oerlinghausen but Ulrich Schwabe, one of the two editors of the Drug Prescription Report. Different from the chapter “Psychotropic Drugs”, the chapter on “Antidementia Drugs” is written objectively and scientifically throughout.
Prescription of antidementia drugs has changed considerably in the last decade in Germany.
Today I want to once again report from the 51st Congress of the American College of Neuropsychopharmacology (ACNP), 2nd – 6th December 2012 in Hollywood, Florida, even though the Congress has already ended. The study was presented as a poster, but I believe it could have been also presented in the “Highlights” session, in which unfortunately the preclinical work dominated (see my last posting dated 12/04/2012).
At least in Germany, acetylcholinesterase inhibitors still have the reputation of being of dubious benefit in patients with dementia of the Alzheimer’s type. It is widely believed that their effect is limited and is in no way proportionate to the adverse effects and costs.
In the latest online issue of the journal Stroke a European research consortium, which also includes a German group (Department of Neurology, University of Heidelberg, Klinikum Mannheim), could again demonstrate that even very modest physical activity significantly reduces the risk of developing dementia (Verdelho et al., Stroke 2012, in press).
The LADIS (Leukoaraiosis and Disability) study prospectively investigates the role of CT or MRI white matter changes for later development of disability. Leukoaraiosis describes diffuse white matter abnormalities, as they are often observed in CT or MRI scans as incidental findings in healthy individuals. In recent years it has become increasingly clear that such changes frequently occur in people with vascular risk factors and that they appear to have some significance for the development of cerebrovascular diseases and dementia .
In the paper just published Continue reading